Safety and PK of Intrathecal CNTX-3001 for Intractable Chronic Low Back Pain
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Lower Back Pain
In brief
This clinical study is being conducted to evaluate the safety, tolerability, plasma pharmacokinetics and efficacy of an investigational drug called CNTX-3001. This Phase 1 study is the first time that CNTX-3001 will be given to people (first-in-human study). The study is being done to evaluate whether CNTX-3001, given into the intrathecal space by lumbar puncture, can be administered safely to participants who have been diagnosed with intractable chronic moderate to severe low back pain and who have not responded well to other treatments in the past. CNTX-3001 is a novel, non-opioid small molecule
Key facts
- Study ID
- NCT07122453
- Run by
- Centrexion Therapeutics
- People needed
- 16
- Starts
- 2026-03-01
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-03-23
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Neurovations — Napa, California, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.